On June 15, 2021 eFFECTOR Therapeutics, Inc. ("eFFECTOR"), a biopharmaceutical company focused on pioneering the development of selective translation regulation inhibitors ("STRIs") for the treatment of cancer, reported that Steve Worland, Ph.D., president and chief executive officer of eFFECTOR, and Chris Ehrlich, chief executive officer and director of Locust Walk Acquisition Corp. (NASDAQ: LWAC), a special purpose acquisition company, will present a company overview at the JMP Securities 2021 Life Sciences Conference on Thursday, June 17 at 2:00 p.m. ET (Press release, eFFECTOR Therapeutics, JUN 15, 2021, View Source [SID1234583983]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast will be accessible from the "Events and Presentation" page of the "News" section of the eFFECTOR’s website (www.effector.com).

As previously announced on May 27, 2021, eFFECTOR entered into a definitive Agreement and Plan of Merger (the "Merger Agreement") with LWAC and Locust Walk Merger Sub, Inc., a wholly owned subsidiary of LWAC ("Merger Sub"). Upon the closing of the transaction, anticipated to occur in the third quarter of 2021, subject to approval of LWAC stockholders and the satisfaction or waiver of certain other customary closing conditions, the combined company will be named eFFECTOR Therapeutics, Inc. and is expected to be listed on the Nasdaq Capital Market under the ticker symbol "EFTR".